Loading...
01/11 07:56
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong dietary supplement revenue growth and improved gross profit margins are offset by declining procedure revenue and increased SG&A expenses. The strategic restructuring and vertical integration are positive, but operational risks and potential challenges in achieving procedure revenue growth temper optimism. The Q&A reveals management's cautious stance on procedure revenue growth and a lack of clarity on certain inefficiencies. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Total Revenue $49,000,000, an increase of 4.7% year-over-year, driven by strong performance in the dietary supplements business.
Procedure Revenue $36,000,000, a decrease of 3.6% year-over-year, primarily due to reduced commercial effectiveness, a slowdown in new clinic additions, and a minor decrease in procedure volumes.
Dietary Supplement Revenue $9,300,000, an increase of 25.5% year-over-year, primarily driven by growth in the e-commerce channel.
Gross Profit Margin 74.3%, an increase of 300 basis points year-over-year, due to cost savings from vertical integration of the 503B manufacturing facility.
Selling, General and Administrative Expenses (SG&A) $26,700,000, an increase of 16.4% year-over-year, reflecting increased investment in sales and marketing to drive new customer growth.
Net Income $15,800,000, compared to a net loss of $5,700,000 in the first quarter of 2024, primarily due to a gain from a change in the fair value of earn-out liabilities.
Diluted Earnings Per Share $0.37, compared to a diluted loss per share of $0.12 in the first quarter of 2024.
Adjusted EBITDA $13,800,000, a decrease of 3.4% year-over-year, primarily reflecting increased sales and marketing expenses.
Cash Flow from Operations $6,500,000 for the first quarter.
Cash and Cash Equivalents $41,700,000 as of 03/31/2025, compared to $39,300,000 as of 12/31/2024.
Dietary Supplements Revenue: Increased 25.5% to $9,300,000 primarily driven by growth in the e-commerce channel.
Procedure Revenue: Decreased 3.6% to $36,000,000 due to reduced commercial effectiveness and a slowdown in new clinic additions.
Gross Profit Margin: Increased 300 basis points to 74.3% due to vertical integration of the 503B manufacturing facility.
Sales Force Expansion: Field sales team increased by approximately 25% to drive new clinic growth.
Sales Compensation Structure: Updated to align incentives with sales goals.
Organizational Restructuring: Announced to drive sustainable profitable growth and create long-term value for stockholders.
Focus Areas for 2025: 1. Accelerate new provider wins 2. Maximize value from top-tier clinics 3. Improve commercial accountability and discipline.
Competitive Pressures: The company is facing ongoing competitive pressures that have impacted procedure revenue, particularly due to reduced commercial effectiveness and a slowdown in new clinic additions.
Regulatory Issues: The transition to enhanced clinical decision support software has caused disruptions, affecting new starts and overall procedure volumes.
Supply Chain Challenges: While the company does not currently see significant exposure to tariffs, it has increased inventory coverage to mitigate potential risks from overseas suppliers.
Economic Factors: There is uncertainty regarding macroeconomic conditions affecting consumer behavior, although no significant softness in price sensitivity has been reported.
Financial Performance Risks: The company anticipates a transition year in 2025, with potential risks to achieving the projected 2% to 4% growth in procedure revenue, dependent on the successful execution of strategic initiatives.
Operational Risks: The restructuring plan may cause temporary disruptions, but is aimed at long-term growth and improved commercial execution.
Key Initiatives: Focus on three major objectives: 1) Accelerate new provider wins, 2) Strengthen relationships with existing top-tier providers, 3) Improve financial performance through accountability and discipline.
Organizational Restructuring: Announced a strategic organizational restructuring to drive sustainable profitable growth and create long-term value for stockholders, including a 25% increase in the field sales team.
Sales Force Realignment: Transitioning commercial support functions to active field sales positions to enhance productivity and drive new clinic growth.
Product Offering Expansion: Significantly expanded capabilities and product offerings in hormone optimization, therapeutic wellness, and dietary supplements.
2025 Revenue Guidance: Maintains guidance of revenue between $200 million to $208 million.
Adjusted EBITDA Guidance: Adjusted EBITDA expected to be between $59 million to $64 million.
Q2 2025 Expectations: Expect revenue and adjusted EBITDA to be similar to or slightly higher than Q2 2024.
One-time Charge: Anticipates a one-time charge of approximately $600,000 to $800,000 in Q2 2025 due to restructuring.
Shareholder Return Plan: The company announced a strategic organizational restructuring aimed at driving sustainable profitable growth and creating long-term value for stockholders. This includes a focus on accelerating new provider wins, strengthening relationships with existing top-tier providers, and improving financial performance through enhanced accountability and discipline. Additionally, the company is updating its sales compensation structure to align incentives with sales goals.
Cash Flow: First quarter cash flow from operations was $6,500,000. As of 03/31/2025, cash and cash equivalents were $41,700,000.
Financial Outlook: The company maintains its guidance for 2025 with expected revenue between $200,000,000 to $208,000,000 and adjusted EBITDA of $59,000,000 to $64,000,000.
Restructuring Costs: The company expects to incur a one-time charge of approximately $600,000 to $800,000 in the second quarter of 2025 due to the restructuring.
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
The earnings call presents a mixed picture: strong dietary supplement revenue growth and improved gross profit margins are offset by declining procedure revenue and increased SG&A expenses. The strategic restructuring and vertical integration are positive, but operational risks and potential challenges in achieving procedure revenue growth temper optimism. The Q&A reveals management's cautious stance on procedure revenue growth and a lack of clarity on certain inefficiencies. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Biote's earnings call presents mixed signals. The company shows strong revenue growth and cost management, but guidance has been lowered, and net income has decreased. The software transition has affected procedure volumes, causing short-term disruptions. The lack of a shareholder return plan and uncertainties around new practitioner growth add to the neutral sentiment. However, the positive cash flow and gross margin improvements provide some optimism. With no market cap data, the overall prediction is neutral, considering the potential for recovery post-software transition and ongoing cost management efforts.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
